Resistances of Mycobacterium tuberculosis in Ferrol, Spain. Associated factors;Resistencias de Mycobacterium tuberculosis en Ferrol. Factores asociados

Medicina Clinica

Volumn 113, Issue 15, 1999, Pages 572-574

  García Rodríguez, José Francisco ^a,b   Mariño Callejo, Ana ^a   Lorenzo García, María Virginia ^a   Rodríguez Mayo, María ^a   Domínguez Gómez, Domingo ^a   Sásma Sénchez, Pascual ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NONE   (Spain)

Author keywords

Drug resistance; Epidemiology; HIV; Tuberculosis; Tuberculosis multidrug resistant

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTION AND FORECASTING; PROSPECTIVE STUDY;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 0033530322     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1.641-1.649.
2. Arévalo M, Solera J, Cebrién D, Bartolomé J, Robles P. Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-La Mancha (Spain). Eur Respir J 1996; 9: 274-278.
3. Gordin FM, Nelson ET, Matts JP, Conn DL, Ernst J, Benator D et al. The impact of Human Immunodeficiency Virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 154: 1.478-1.483.
4. García Rodríguez JF. La tuberculosis en Ferrol. Período 1990-1996 [tesis doctoral], Universidad de La Corurĩa, 1998.
5. Canetti G, Rist J, Grosset J. Measure de la sensibilité du bacille :uberculeux aux drogues antibacillaires par la methode des proportions. Methodologie, critere de reistance, resultats, interpretation. Rev Tub Pneumo 1963; 27: 217-272.
6. Vareldzis BP, Grosset J, Kantor I, Crofton J, Laszlo A, Felten M et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuberc Lung Dis 1994; 75: 1-7.
7. Alberte A, Pérez F, Grupo de microbiólogos de Castilla y Léon. Resistencias primarias de Mycobacterium tuberculosis en diez hospitales de la Comunidad de Castilla y Léon. Rev Clin Esp 1999; 199: 132-135.
8. Ausina V, Riutort N, Viñado B, Manterola JM, Ruiz Manzano J, Rodrigo C et al. Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection. Eur J Clin Microbiol Infect Dis 1995; 14: 105-11C.
9. Peña JM, Ortega A. Grupo de Estudio de Tuberculosis Resistente de Madrid. Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994). Med Clin (Barc) 1996; 106: 1-6.
10. Weis SE, Slocum PC, Biais FX, King B, Nunn M, Matney B et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1.179-1.184.